AbbVie abandons a pioneering CRISPR R&D alliance with Editas as Brent Saunders' deal is cast out
A little more than 3 years ago Allergan paid $90 million in a cash upfront to partner with gene editing player Editas on a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
